Product Description
NN3201, a novel c-Kit targeting antibody-drug conjugate (ADC), comprised of fully human 2G4 antibody with a picomolar binding affinity to c-Kit and cytotoxic monomethyl auristatin E (MMAE) as the payload. NN3201 displayed potent in vitro cytotoxicity in various wild-type and mutant c-Kit positive SCLC and GIST cell lines with IC50 in the nanomolar range. In addition, NN3201 was rapidly internalized and inhibited c-Kit-mediated signaling. (Sourced from: https://aacrjournals.org/cancerres/article/84/6_Supplement/3142/735445/Abstract-3142-NN3201-a-novel-c-Kit-targeting-ADC)
Mechanisms of Action: C-KIT Inhibitor,Tubulin Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novelty Nobility, Inc.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Adenoid Cystic Carcinoma|Gastrointestinal Cancer|Gastrointestinal Stromal Tumors|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Renal Cell Carcinoma|Small Cell Lung Cancer|Uveal Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NN3201-ST100 | P1 |
Recruiting |
Small Cell Lung Cancer|Renal Cell Carcinoma|Gastrointestinal Cancer|Gastrointestinal Stromal Tumors|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Uveal Melanoma|Adenoid Cystic Carcinoma |
2027-08-30 |
23% |
2025-02-14 |
Primary Endpoints|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|